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Background: Infliximab has been shown to be effective in achieving clinical remission in patients with
ulcerative colitis (UC) refractory to conventional therapy. However, there is conflicting data in the
literature regarding its effectiveness as rescue therapy in acute severe colitis. Furthermore, most
studies were conducted in adults, and pediatric onset of inflammatory bowel disease (IBD) is
associated with more severe disease that may be less amenable to rescue therapy.
Objectives/Goal: We reviewed our experience with pediatric severe colitis and report outcomes
following attempted rescue therapy with infliximab.
Methods/Design: A retrospective review was conducted of patients with UC or indeterminate colitis
who received rescue infliximab therapy at our institution from January 2000-January 2019. Rescue
infliximab therapy was considered if a child failed non-biologic therapy or progressed to fulminant or
toxic colitis. Primary outcome was failed therapy resulting in colectomy. Secondary outcomes included
number of admissions, antibiotic utilization, total parental nutrition (TPN) days, number of blood
transfusions, imaging, number of laboratory tests, days of intravenous steroids, and length of stay.
Statistical analysis was performed using STATA and a p-value of <0.05 determined significance.
Results: Thirty patients met inclusion criteria. The median age at administration of rescue infliximab
treatment was 14.5 years [IQR 13, 17]. Rescue therapy with infliximab was successful in 33% (n=10),
while 67% (n=20) underwent colectomy. Comparisons of clinical characteristics of those with

successful infliximab rescue versus those who underwent colectomy are shown in Table 1. Children on
maintenance steroids were less likely to have successful rescue with infliximab and require colectomy
(p=0.03). Possibly indicative of rescue therapy, children requiring colectomy had a longer hospital stay
(p=0.03), more abdominal radiographs (p=0.01), and were on a longer duration of antibiotics
(p=<0.01) compared to children who were successfully rescued with infliximab. There was no
difference between children successfully salvaged with infliximab and those who required colectomy
with regards to vital signs or lab abnormalities, specifically white blood cell count and electrolyte
values.
Conclusions: Infliximab as rescue therapy is ineffective in two-thirds of pediatric patients with
severe colitis and does not have the potential for long-term cure. A response is more likely when
patients are not on steroids at the time of admission.
Table 1: Comparison of clinical characteristics in pediatric patients with successful infliximab rescue
versus those who required colectomy. Continuous variables are expressed as medians with interquartile ranges.

Clinical Features

Steroids

Hospital Course

Age (years)
Toxic Colitis
Fever >38
HR>120
WBC >10.5
Electrolyte
Disturbance
Hypotension
Maintenance
Steroids
Steroid Days
LOS (days)
Antibiotic Days
Central Line
Number of KUBs

Successful
Rescue
N=10
13 [7, 15]
20%
10%
30%
60%

Colectomy
N=20

p-value

13.5 [11, 15.5]
45%
25%
45%
80%

0.89
0.25
0.63
0.69
0.38

33%

65%

0.23

50%

25%

0.23

60%

95%

0.03

9.5 [2, 20]
14 [3, 27]
0 [0, 0]
50%
0.5 [0, 2]

26.5 [7, 36.5]
27.5 [13.5, 35]
10 [3, 16.5]
85%
2.5 [1, 4]

0.09
0.03
<0.01
0.08
0.01

*HR = heart rate, WBC = white blood cell count, LOS = length of stay, KUB = abdominal radiograph

